Literature DB >> 8318785

Lidocaine metabolite formation as a measure of perioperative liver function.

K Shimanuki1, I Sakurabayashi, M Miyata, H Kiyozaki, W Suzuki, A Kashii, N Seo.   

Abstract

In order to determine whether lidocaine metabolism, as the formation of monoethylglycinexylidide (MEGX), could be used as a quantitative index of perioperative liver function, serum levels of MEGX in 31 surgical patients were measured and compared with the results of conventional liver function tests. A significant correlation was found between the values of MEGX and ICGR15 in 20 of the 31 patients. The values of ICGR15 were lower than 20% in patients whose MEGX values were above 60 ng/ml and 20% or higher in those with MEGX values of lower than 60 ng/ml. There was also a significant correlation between MEGX values and antithrombin III values, and between MEGX values and the postoperative maximum levels of aspartate aminotransferase. However, no correlation was found between MEGX values and other preoperative conventional liver function tests in any of the 31 patients. We suggest that a cut-off MEGX value of 60 ng/ml be used as an indicator for satisfactory preoperative liver function. MEGX formation could be a useful prognostic index for patients who have undergone surgical procedures for liver disease, and employed as a quantitative assessment of perioperative liver function.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8318785     DOI: 10.1007/bf00309048

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  8 in total

1.  Liver function assessment by drug metabolism.

Authors:  L Barstow; R E Small
Journal:  Pharmacotherapy       Date:  1990       Impact factor: 4.705

2.  Assessment of lidocaine metabolite formation as a quantitative liver function test in children.

Authors:  D A Gremse; H H A-Kader; T J Schroeder; W F Balistreri
Journal:  Hepatology       Date:  1990-09       Impact factor: 17.425

3.  Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease.

Authors:  J A Forrest; N D Finlayson; K K Adjepon-Yamoah; L F Prescott
Journal:  Br Med J       Date:  1977-05-28

4.  Lignocaine metabolite formation as a measure of pre-transplant liver function.

Authors:  M Oellerich; M Burdelski; B Ringe; P Lamesch; G Gubernatis; H Bunzendahl; R Pichlmayr; H Herrmann
Journal:  Lancet       Date:  1989-03-25       Impact factor: 79.321

5.  Determinants of drug disposition in patients with cirrhosis.

Authors:  P M Huet; J P Villeneuve
Journal:  Hepatology       Date:  1983 Nov-Dec       Impact factor: 17.425

6.  Monoethylglycinexylidide formation kinetics: a novel approach to assessment of liver function.

Authors:  M Oellerich; E Raude; M Burdelski; M Schulz; F W Schmidt; B Ringe; P Lamesch; R Pichlmayr; H Raith; M Scheruhn
Journal:  J Clin Chem Clin Biochem       Date:  1987-12

7.  Influence of liver disease and environmental factors on hepatic monooxygenase activity in vitro.

Authors:  M J Brodie; A R Boobis; C J Bulpitt; D S Davies
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

8.  Anaphylactic reaction to lidocaine.

Authors:  K S Kennedy; R H Cave
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1986-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.